Acelyrin Receivables

The latest receivables for SLRN is $0 as of March 2025. That compares with $5.4M in the prior-year period — down 100.0% year over year. Investors often review this figure alongside Acelyrin's historical trend and sector peers before judging valuation or financial health.

Over the past year, SLRN's receivables moved from $5.4M to $0 — a 100.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acelyrin's operating scale or balance-sheet position.

A receivables figure of $0 for SLRN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SLRN's receivables ($0), review year-over-year change from $5.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.